electroCore 2025 Q2 Earnings Sustained Losses Amid 20% Revenue Growth

electroCore (ECOR) reported its fiscal 2025 Q2 earnings on Aug 07th, 2025. The company delivered revenue growth above expectations, but the expansion came alongside a widening net loss. The company did not revise full-year guidance and maintained its strategic focus on R&D and commercial expansion.

Revenue
electroCore’s total revenue rose 20.2% year-over-year to $7.38 million in Q2 2025. The increase was primarily driven by robust sales in its VA segment for prescription gammaCore, as well as strong performance from its nonprescription Truvaga™ and TAC-STIM wellness products. U.S. commercial sales for prescription gammaCore saw a decline, while international sales and Quell-related revenue remained relatively flat. The VA segment for Quell and the VA market overall played a pivotal role in achieving the record revenue quarter.

Earnings/Net Income
Despite the revenue increase, electroCore’s losses worsened. The company reported a net loss of $3.67 million, or $0.44 per share, a 38.3% increase in net loss and 15.8% wider on a per-share basis compared to the prior year. This marked the ninth consecutive year of losses in the corresponding quarter, underscoring ongoing financial challenges.

Price Action
The stock of electroCore showed mixed performance in the immediate aftermath. Shares climbed 1.46% on the latest trading day but dipped 1.28% over the most recent week. Notably, the stock surged 13.79% on a month-to-date basis, reflecting some short-term optimism.

Post-Earnings Price Action Review
A strategy of buying electroCore shares after its Q2 2025 earnings and holding for 30 days has historically underperformed. Over the past three years, the approach yielded a return of -44.78%, compared to a 49.40% benchmark return. This produced an excess return of -94.18% and a compound annual growth rate of -18.13%, signaling significant underperformance and a lack of growth in post-earnings momentum.

CEO Commentary
Dan Goldberger, CEO of electroCore, highlighted the return to normalized growth in the Veterans Administration (VA) market, which contributed to the record revenue quarter and 20% year-over-year growth. He noted that the company significantly reduced cash outflows to approximately $614,000 in Q2 and completed the NURO acquisition ahead of schedule. Goldberger emphasized continued investment in U.S. sales and marketing, as well as the long-term relevance of electroCore’s solutions in the VA space.

Guidance
For the remainder of 2025, electroCore expects higher R&D expenses than in the same periods of 2024. The company will continue targeted investments in sales and marketing to support commercial efforts but did not provide specific revenue or EPS guidance. Instead, it anticipates continued growth and operational focus on integration and market expansion.

Additional News
On August 6, 2025, electroCore announced its second quarter 2025 financial results, revealing a 20% year-over-year increase in net sales to $7.4 million. The company successfully raised $7.2 million in net proceeds through a term debt facility, and as of June 30, 2025, it reported cash and marketable securities totaling $7.4 million. A conference call and webcast were held on the same day to discuss the results. The company also announced the successful completion of the NeuroMetrix, Inc. (NURO) acquisition ahead of schedule, signaling a strategic shift in its business expansion efforts.